-
1
-
-
68949149916
-
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents
-
Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009;61: 451-485.
-
(2009)
J Am Acad Dermatol.
, vol.61
, pp. 451-485
-
-
Menter, A.1
Korman, N.J.2
Elmets, C.A.3
Feldman, S.R.4
Gelfand, J.M.5
Gordon, K.B.6
-
2
-
-
0037331055
-
The combination of calcipotriol and methotrexate compared with methotrexate and vehicle in psoriasis: Results of a multicentre placebo-controlled randomized trial
-
De Jong EM, Mork NJ, Seijger MM, De La Brassine M, Lauharanta J, Jansen CT, et al. The combination of calcipotriol and methotrexate compared with methotrexate and vehicle in psoriasis: Results of a multicentre placebo-controlled randomized trial. Br J Dermatol. 2003;148:318-325.
-
(2003)
Br J Dermatol.
, vol.148
, pp. 318-325
-
-
De Jong, E.M.1
Mork, N.J.2
Seijger, M.M.3
De La Brassine, M.4
Lauharanta, J.5
Jansen, C.T.6
-
3
-
-
0031883423
-
Calcipotriol improves the efficacy of cyclosporine in the treatment of psoriasis vulgaris
-
Kokelj F, Torsello P, Plozzer C. Calcipotriol improves the efficacy of cyclosporine in the treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol. 1998;10:143-146.
-
(1998)
J Eur Acad Dermatol Venereol.
, vol.10
, pp. 143-146
-
-
Kokelj, F.1
Torsello, P.2
Plozzer, C.3
-
4
-
-
6844260549
-
The effect of addition of calcipotriol ointment (50 micrograms/g) to acitretin therapy in psoriasis
-
van de Kerkhof PC, Cambazard F, Hutchinson PE, HanekeW, Wong E, Souteyrand P, et al. The effect of addition of calcipotriol ointment (50 micrograms/g) to acitretin therapy in psoriasis. Br J Dermatol. 1998;138:84-89.
-
(1998)
Br J Dermatol.
, vol.138
, pp. 84-89
-
-
Van De Kerkhof, P.C.1
Cambazard, F.2
Hutchinson, P.E.3
Haneke, W.4
Wong, E.5
Souteyrand, P.6
-
5
-
-
80051726700
-
S3-guidelines for the treatment of psoriasis vulgaris Update 2011
-
Nast A, Boehncke WH, Mrowietz U, Ockenfels HM, Philipp S, Reich K, et al. S3-guidelines for the treatment of psoriasis vulgaris Update 2011. J Dtsch Dermatol Ges. 2011;9 (Suppl 2):S1- S104.
-
(2011)
J Dtsch Dermatol Ges.
, vol.9
, Issue.SUPPL. 2
-
-
Nast, A.1
Boehncke, W.H.2
Mrowietz, U.3
Ockenfels, H.M.4
Philipp, S.5
Reich, K.6
-
6
-
-
70249137988
-
European S3-guidelines on the systemic treatment of psoriasis vulgaris
-
Pathirana D, Ormerod AD, Saiag P, Smith C, Spuls PI, Nast A, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2009;23(Suppl 2):1-70.
-
(2009)
J Eur Acad Dermatol Venereol.
, vol.23
, Issue.SUPPL. 2
, pp. 1-70
-
-
Pathirana, D.1
Ormerod, A.D.2
Saiag, P.3
Smith, C.4
Spuls, P.I.5
Nast, A.6
-
7
-
-
10744221697
-
A randomized trial of etanercept as monotherapy for psoriasis
-
Gottlieb AB, Matheson RT, Lowe N, Kruegger GG, Kang S, Goffe BS, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol. 2003;139:1627-1632.
-
(2003)
Arch Dermatol.
, vol.139
, pp. 1627-1632
-
-
Gottlieb, A.B.1
Matheson, R.T.2
Lowe, N.3
Kruegger, G.G.4
Kang, S.5
Goffe, B.S.6
-
8
-
-
0344926414
-
Etanercept as monotherapy in patients with psoriasis
-
Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349:2014-2022.
-
(2003)
N Engl J Med.
, vol.349
, pp. 2014-2022
-
-
Leonardi, C.L.1
Powers, J.L.2
Matheson, R.T.3
Goffe, B.S.4
Zitnik, R.5
Wang, A.6
-
9
-
-
21644481166
-
A global phase III randomized controlled trial of etanercept in psoriasis: Safety, efficacy, and effect of dose reduction
-
Papp KA, Tyring S, Lahfa M, Prinz J, Griffiths C, Nakanishi AM, et al. A global phase III randomized controlled trial of etanercept in psoriasis: Safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005;152:1304-1312.
-
(2005)
Br J Dermatol.
, vol.152
, pp. 1304-1312
-
-
Papp, K.A.1
Tyring, S.2
Lahfa, M.3
Prinz, J.4
Griffiths, C.5
Nakanishi, A.M.6
-
10
-
-
54249097066
-
Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: A randomized controlled trial with open-label extension
-
van de Kerkhof PC, Segaert S, Lahfa M, Luger TA, Karolyi Z, Kaszuba A, et al. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: A randomized controlled trial with open-label extension. Br J Dermatol. 2008;159:1177-1185.
-
(2008)
Br J Dermatol.
, vol.159
, pp. 1177-1185
-
-
Van De Kerkhof, P.C.1
Segaert, S.2
Lahfa, M.3
Luger, T.A.4
Karolyi, Z.5
Kaszuba, A.6
-
11
-
-
0032717253
-
Measuring health-related quality of life in patients with mild to moderate eczema and psoriasis: Clinical validity, reliability and sensitivity to change of the DLQI. The cavide research group
-
Badia X, Mascaro JM, Lozano R. Measuring health-related quality of life in patients with mild to moderate eczema and psoriasis: Clinical validity, reliability and sensitivity to change of the DLQI. The cavide research group. Br J Dermatol. 1999; 141:698-702.
-
(1999)
Br J Dermatol.
, vol.141
, pp. 698-702
-
-
Badia, X.1
Mascaro, J.M.2
Lozano, R.3
-
12
-
-
18944404879
-
Current severe psoriasis and the rule of tens
-
Finlay AY. Current severe psoriasis and the rule of tens. Br J Dermatol. 2005;152:861-867.
-
(2005)
Br J Dermatol.
, vol.152
, pp. 861-867
-
-
Finlay, A.Y.1
-
13
-
-
33750492269
-
The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: Results of a phase II study
-
Shikiar R, Willian MK, Okun MM, Thompson CS, Revicki DA. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: Results of a phase II study. Health Qual Life Outcomes. 2006;4:71.
-
(2006)
Health Qual Life Outcomes.
, vol.4
, pp. 71
-
-
Shikiar, R.1
Willian, M.K.2
Okun, M.M.3
Thompson, C.S.4
Revicki, D.A.5
-
14
-
-
76149102966
-
Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial
-
Sterry W, Ortonne JP, Kirkham B, Brocq O, Robertson D, Pedersen RD, et al. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ. 2010;340:c147.
-
(2010)
BMJ
, vol.340
-
-
Sterry, W.1
Ortonne, J.P.2
Kirkham, B.3
Brocq, O.4
Robertson, D.5
Pedersen, R.D.6
-
15
-
-
70449492883
-
Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: The crystel study
-
Dauden E, Griffiths CE, Ortonne JP, Kragballe K, Molta CT, Robertson CD, et al. Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: The CRYSTEL study. J Eur Acad Dermatol Venereol. 2009;23: 1374-1382.
-
(2009)
J Eur Acad Dermatol Venereol.
, vol.23
, pp. 1374-1382
-
-
Dauden, E.1
Griffiths, C.E.2
Ortonne, J.P.3
Kragballe, K.4
Molta, C.T.5
Robertson, C.D.6
|